GM-CSF transgenic mice were crossed with mice with homozygous inactivation of the gene encoding the common ␤ chain (␤c) of the GM-CSF receptor to produce mice with constitutively elevated GM-CSF levels but no high-affinity GM-CSF receptors. GM-CSF transgenic ␤c ؊/؊ mice had exceptionally elevated serum GM-CSF levels but failed to develop the abnormal peritoneal cell population, eye destruction or tissue lesions characteristic of GM-CSF transgenic ␤c ؉/؉ mice. The alveolar proteinosis of ␤c ؊/؊ mice was not altered in GM-CSF transgenic ␤c ؊/؊ mice. Levels of GM-CSF mRNA in transgenic GM-CSF ␤c ؊/؊ were elevated but lower than in transgenic ␤ ؉/؉ mice and the higher serum GM-CSF levels were traced in part to the longer serum half-life of GM-CSF in ␤c ؊/؊ than in ␤c ؉/؉ mice although urinary loss of GM-CSF was higher in ␤c ؊/؊ than in ؉/؉ mice. The data indicate that the transgenic phenotype was due to stimulation by GM-CSF and not an insertional effect, that low-affinity receptors are not capable of initiating tissue pathology even in the presence of excess GM-CSF levels and that autocrine production of GM-CSF by GM-CSFresponsive cells also fails to induce changes in these cells. The results support current dogma that the action of polypeptide regulators is mediated exclusively by activation of high-affinity membrane receptors.
Introduction
Commencing two decades ago, there has been a progressive recognition that specific membrane receptors exist for polypeptide regulators and that these mediate interactions between the regulators and their responding target cells. Individual specific receptor chains are transmembrane proteins, of low affinity for their respective ligands.
Although polypeptide regulators themselves have a highly complex three-dimensional structure, current views have downgraded the role of regulators to that of merely acting as cross-linking agents bringing together two or more receptor chains, with all signaling events originating from subsequent cross-activation of the receptor chains. Receptor-ligand complexes are rapidly internalized, the complex is then dissociated in intracellular endosomes, usually after fusion with lysosomes, and the ligand (regulator) degraded by proteolysis. 1 No significant functional role is ascribed either to lowaffinity complexes of the regulator with its specific ␣ receptor chain or to the regulator molecules themselves after entry into the cells.
In the context of leukemic cells, where transformation often involves an acquired capacity by the cells to produce their own relevant polypeptide growth factors, [2] [3] [4] these current views warrant reanalysis. Is it certain that intracellular growth factors have no action on responsive cells in the absence of high-affinity receptors? Can the regulator molecules themCorrespondence: D Metcalf; Fax: 61-3-9347-0852 Received 29 September 1997; accepted 14 November 1997 selves elicit some cellular responses, acting alone or when complexed merely with low-affinity ␣-chain receptors? What is the situation when excessive amounts of regulators are being produced inside responsive cells?
The present study involved granulocyte-macrophage colony-stimulating factor (GM-CSF), a glycoprotein hematopoietic regulator with major proliferation actions on neutrophilic granulocytes, monocyte-macrophages and eosinophils and an ability to functionally activate macrophages. 5, 6 The GM-CSF receptor is a heterodimer composed of a low-affinity specific ␣-chain and a signaling ␤-chain (␤c) which is shared in common by the specific ␣-receptor chains for IL-5 and IL-3. 5 Most evidence indicates that the ␤-chain initiates signaling events 5 but there has been one report of membrane transport responses initiated by the ␣-chain. 7 The specific questions concerning the relative roles played by GM-CSF and its receptor in eliciting cellular responses were addressed by developing a transgenic mouse producing excessive levels of GM-CSF but possessing no signaling GM-CSF ␤-receptor chains, and thus no high-affinity GM-CSF receptors. GM-CSF transgenic, ␤c −/− mice were analyzed for the development of the macrophage population changes and organ damage characteristic of GM-CSF transgenic mice.
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The opportunity was also taken with these mice to study the pattern of tissues producing GM-CSF in excessive amounts and, in non-transgenic ␤c −/− mice, to study the plasma halflife of GM-CSF and in particular the renal clearance of GM-CSF in animals lacking high-affinity GM-CSF receptors.
Materials and methods

Mice
The production of heterozygous GM-CSF transgenic (C57BL × SJL)F 2 mice (GM-CSF transgenic mice) has been described previously. 9 The transgenic state is identifiable clinically by the small size and opaque appearance of the eye. For the present studies, mice were also identified by Southern analysis of tail DNA after enzyme digestion to identify the additional band originating from the insertion of two transgene copies of the GM-CSF gene. 9 The production of mice with homozygous inactivation of the gene encoding the common ␤-chain of the GM-CSF receptor has been described previously.
11 These mice were identified by a PCR-based analysis of tail DNA. Tail DNA was prepared and 1 l was amplified in a PCR reaction mixture containing ␤c primers 5′ GTG TAG ACA CTG GCC CCC G-3′  and 5′ GAA CCT TCA ATG CTT CTT TGA TGG GAT-3′ and  neo primer 5′-ATA TTG CTG AAG AGC TTG GCG GC-3′.  Reaction conditions were 96°C 30 s, 60°C 50 s, 72°C 3 inactivation of the ␤c GM-CSF receptor was achieved by first crossing heterozygous GM transgenic mice with homozygous ␤c −/− mice then mating offspring that were ␤c +/− and GM-CSF transgenic +/−. Grouping together the mice that were homozygous or heterozygous for the GM-CSF transgene, this cross yielded mice of six genotypes as shown in Table 1 . All analyses were made on mice aged between 2 and 3 months that were raised in specific pathogen-free quarters.
Analyses
White cell counts were performed under penthrane anesthesia on orbital plexus blood then the mice were killed by collecting the blood from the axillary vessels. At this time, urine samples were also collected and subsequently passed through a NAP-5 column (Pharmacia, Uppsala, Sweden) to remove toxic low molecular weight inhibitors. Sera were collected, diluted 1:4 with saline then millipore filtered. Peritoneal cells were collected by injecting 2 ml of 5% fetal calf serum in 0.9% saline intraperitoneally into the intact abdomen, then gently massaging the abdomen and harvesting the cell suspension using a soft plastic Pasteur pipette. Marrow cells were collected from one femur shaft for counting and analysis of cytocentrifuge suspensions after staining with May-Grü newald Giemsa.
The organs were then removed and fixed in 10% formalin in 0.9% saline. Histological analysis was performed on both eyes, the salivary gland, thymus, heart, lung, liver, diaphragm, spleen, mesenteric lymph node, kidney, bladder, small and large intestine, pancreas, uterus and ovaries or testis and seminal vesicles, brain, skin, skeletal muscle, sternum and one femur plus tibia.
GM-CSF assays
Assays for GM-CSF in serum, urine and peritoneal cellconditioned media were performed using 60 well microtiter trays, each well containing 200 FDC-P1 cells in 10 l volumes of Dulbecco's modified Eagle's medium with 10% newborn calf serum and duplicate serial two-fold dilutions of the test material in 5 l volumes. 12 Cultures were scored after 48 h of incubation at 37°C in a fully humidified atmosphere of 10% CO 2 and the GM-CSF content of test specimens calculated as ng/ml, using for calibration parallel titrations of a purified recombinant murine GM-CSF standard containing 1 ng/ml. The lower detection level of the assay was 100 pg/ml and because serum samples were initially diluted 1:4, the lower detection limit for serum GM-CSF was 400 pg/ml. Because of the use of serial two-fold dilutions in the assays, the mean data from groups of mice were expressed as geometric means and in the Tables the actual ranges of values observed are also indicated.
Serum GM-CSF half-life and renal clearance studies ␤c −/− and ␤c +/+ mice were injected intravenously with 0.2 ml of 5% fetal calf serum in 0.9% saline containing either 400 ng or 2000 ng purified recombinant murine GM-CSF, either non-glycosylated as produced by E. coli or glycosylated as produced by murine erythroleukemia cells. Renal clearance studies were performed by holding individual mice in metabolism cages for 5 h following the intravenous injection of GM-CSF in a volume of 0.4 ml to promote unine production.
Production of GM-CSF by peritoneal cells
Suspension cultures were prepared in 1 ml volumes of Dulbecco's modified Eagle's medium containing 10% newborn calf serum in 35-mm Petri dishes using 1 × 10 6 peritoneal cells. Medium was collected from replicate cultures after 3 and 6 h of incubation at 37°C in a fully humidified atmosphere of 10% CO 2 in air. Production of GM-CSF by adherent peritoneal cells (Ͼ95% macrophages) was performed by incubating 1 × 10 6 peritoneal cells in the culture dishes for 3 h then washing non-adherent cells free by three cycles of washing. Adherent cells were then incubated in fresh medium for a second 3-h period before collection of the medium for GM-CSF assays.
RNA extraction and RT-PCR
Total RNA was extracted from the organs of adult male mice as previously described. 13 Oligo-dT-primed first strand cDNA was synthesized from 5 g of total RNA using 'Ready-To-Go' reaction mixes (Pharmacia). RT-PCR was performed using previously described oligonucleotide primers and methods 12 with the following modifications. Template cDNA from each organ was initially tested for ␤-actin amplification and then appropriate amounts used for specific amplification of GM-CSF sequences. 20 l reactions containing template cDNA, 200 M dNTPs, 1 M primers, 0.5 Units Taq DNA polymerase (Boehringer) and the buffer supplied by the manufacturer, were cycled 25 times through a 94°C/30 s, 60°C/30 s, 72°C/30 s amplification protocol. Amplified products were separated by 1% agarose gel electrophoresis, transfered to GeneScreen Plus nylon membrane (NEN Life Sciences, Boston, MA, USA) and hybridized with oligonucleotides located internally to the primers used for amplification. Specific RT-PCR products were visualized by autoradiography.
Autoradiography of tissues
Non-glycosylated purified recombinant GM-CSF was labeled with 125 I using methods described previously. 14 125 I-GM-CSF in Dulbecco's modified Eagle's medium containing 10% fetal calf serum was injected into 2-month-old ␤c +/+ and ␤c −/− mice using 3 × 10 6 c.p.m. in 0.2 ml. Four hours later, the mice were killed and sections of the organs subjected to autoradiographic analysis as described previously.
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Results Table 1 shows the frequency of the six genotypes resulting from the intermating of heterozygous GM-CSF transgenic ␤c +/− mice. Although some GM-CSF +/+ mice resulted from this intercross, such mice were grouped with the GM-CSF +/− mice because previous studies had indicated no major differences between mice of these two types. Analysis of the first 106 mice from this mating revealed a distribution of genotypes that was very close to the expected ratio. This indicated that none of the genotypes was associated with fetal or neonatal death. Unexpectedly, heterozygous GM-CSF transgenic ␤c +/− mice died somewhat earlier than standard GM-CSF transgenic ␤c +/+ mice and, with the progeny of the mating, all observations were performed on mice under the age of 3 months to avoid complications that could have arisen from the early death of mice of several of the genotypes under analysis.
Analysis of the mice
All observations were performed without prior knowledge of the genotype of the mouse, with the inevitable exception that some mice were readily identifiable as GM-CSF transgenic because of the characteristic opacity of their eyes.
Assays for GM-CSF levels in the serum and urine revealed that all mice typed as GM-CSF transgenic had elevated GM-CSF concentrations in both the serum and urine (Table 2 ). In agreement with earlier studies, male transgenic mice had higher GM-CSF concentrations in the urine than did female mice but the present mice also showed a similar sex difference in serum GM-CSF concentrations. GM-CSF transgenic mice that were also ␤c −/− exhibited two-to five-fold higher mean GM-CSF concentrations in both the serum and urine than were present in GM-CSF transgenic ␤c +/− or ␤c +/+ mice. It is of interest that serum GM-CSF levels varied over a 16-fold range in ␤c −/− mice rather than the usual four-fold variation in ␤c +/− or ␤c +/+ mice. No GM-CSF was detectable in the serum of non-transgenic ␤c +/+ or ␤c +/− mice and most ␤c −/− mice but low levels of GM-CSF were consistently detected in the urine of non-transgenic ␤c −/− mice.
These assays indicated that the tissues of GM-CSF transgenic ␤c −/− mice were being exposed to high GM-CSF concentrations, indeed to concentrations that were significantly higher than in standard GM-CSF transgenic mice. 
Data shown are the geometric means of the observed values and the figures in brackets are the range of values observed.
Changes in peritoneal cell populations
The results of analyzing the peritoneal populations in the present mice are shown in Table 3 . No differences were observed between the peritoneal cell population of nontransgenic mice of any ␤c status. GM-CSF transgenic ␤c +/+ and ␤c +/− mice both showed the changes characteristic of the transgenic state -a massive increase in peritoneal macrophages that are enlarged, basophilic and often binucleate or multinucleate, a rise in eosinophil numbers and an absence of mast cells. 8, 9 Not shown in the Table is the fact that transgenic macrophages also had characteristic uniformly rounded nuclei in contrast to pleiomorphic morphology of normal peritoneal macrophage nuclei (Figure 1) .
In sharp contrast, the peritoneal cells from GM-CSF transgenic ␤c −/− mice exhibited normal total cell numbers, pleiomorphic macrophage nuclear morphology, normal mast cell numbers, no tendency for excessive binucleate or multinucleate macrophage formation, and no eosinophil accumulation (Table 3) . These populations could not be distinguished by any parameter from populations in non-GM-CSF transgenic mice.
Changes in other organs GM-CSF transgenic mice are characterized by a massive destruction of the tissues of the eye. There is destruction of the photoreceptor layer of the retina, commonly destruction and infiltration of the lens and similar damage in the cornea with the presence in both chambers of infiltrating macrophages and usually an overall size reduction and collapse inwards of the eyeball (Figure 2 ). Transgenic GM-CSF mice of both ␤c +/+ and +/− genotype showed an equivalent degree of ocular damage. In sharp contrast, the eyes of GM-CSF transgenic ␤c −/− mice had a normal morphology and showed none of the features characteristic of the GM-CSF transgenic state ( Figure 2 ).
In mice aged only 2 to 3 months, other tissue lesions in GM-CSF transgenic mice are less consistent but some mice can exhibit focal macrophage inflammatory disease in skeletal muscles, nodule formation in the peritoneal or pleural cavity and granuloma formation in the walls of pelvic organs, particularly the bladder. 8, 9 Such lesions were present in some of the GM-CSF transgenic ␤c +/+ and +/− mice surveyed but no 356 
lesions of this nature were seen in any of the GM-CSF transgenic ␤c −/− mice. ␤c −/− mice, like GM-CSF −/− mice, develop a characteristic lung pathology of accumulation of surfactant and proteinaceous material in the alveoli -the disease state, alveolar proteinosis. 11, 16, 17 This is based, in part at least, on defective function of the alveolar macrophages. Associated with this are prominent focal accumulations of T-and B-lymphocytes in the peribronchial regions. GM-CSF transgenic ␤c −/− mice showed lung pathology that was identical in nature and severity to that seen in non-transgenic ␤c −/− mice (Figure 3) , the high circulating GM-CSF levels having no impact on this disease.
Production of GM-CSF by peritoneal macrophages
Previous mRNA studies indicated that macrophages were likely to be major cell populations transcribing GM-CSF in GM-CSF transgenic mice, 9 and serum GM-CSF levels were found to parallel total numbers of peritoneal and pleural macrophages. 18 To document that GM-CSF was being produced by the same peritoneal cells showing the striking phenotypic changes in GM-CSF transgenic mice, 1 ml suspension cultures of 1 × 10 6 peritoneal cells were prepared. Initial experiments using peritoneal cells had shown that concentrations of GM-CSF in the medium of such cultures were often lower after 24 and 48 h of incubation than at earlier timepoints of 3 and 6 h of incubation. Furthermore, most tissues exhibit extensive induction of transcription of CSFs after incubation in vitro for more than 5 h, 12 making estimates of GM-CSF in conditioned medium progressively less likely with time to accurately reflect levels of production that might be occurring in vivo. Because of these problems, incubation periods of only 3 and 6 h were used. In a parallel set of cultures, non-adherent cells were removed after 3 h of incubation, then the residual purified adherent macrophages were incubated for a further 3-h period to establish whether macrophages were producing GM-CSF.
The results obtained using cells of the six genotypes are shown in Table 4 . GM-CSF production was detected in the cultures but the levels observed were highly variable. Despite this, GM-CSF transgenic ␤c +/+ and ␤ +/− cells clearly produced more GM-CSF than corresponding non-transgenic cells. Production of GM-CSF by GM-CSF transgenic ␤c −/− cells was detectable but the levels were lower than with ␤c +/+ or +/− cells and, arguably, no higher than with non-transgenic cells.
Production of GM-CSF by adherent macrophages was detectable but the levels were considerably lower than those observed using unfractionated populations, in part due to the lower numbers of cells being incubated following the removal of non-adherent cells. The data were consistent with the initial description of major GM-CSF transcription in the peritoneal cells of GM-CSF transgenic mice. 9 However, the low production levels by GM-CSF transgenic ␤c −/− cells indicated that the model used had not achieved a notably high level of autocrine GM-CSF production by the cell type most revealing of GM-CSF-induced changes, the peritoneal macrophages.
mRNA levels in various organs
Analysis by PCR of levels of expression of mRNA for GM-CSF in non-transgenic ␤c +/+ mice indicated that very low levels were detectable in a variety of organs but significant levels in the lung, thymus and eye (Figure 4 ). GM-CSF transgenic ␤c +/+ organs shared a similar pattern of expression but at elevated levels. In transgenic organs, expression of GM-CSF mRNA was grossly elevated in peritoneal cells, lung and eye. This confirmed and extended an earlier, less complete, analysis 9 and suggested that the peritoneal (and pleural) transgenic macrophages were a major source of the GM-CSF in these animals, the high content in lung possibly being ascribable to the frequent presence of aggregates of pleural macrophages on the lung surface, and the high levels in the eye to the high macrophage content of the transgenic eye. There was some elevation of mRNA in other tissues, which might again have been ascribable to transgenic macrophages in these tissues.
The results from a parallel analysis of tissues from GM-CSF transgenic ␤c −/− mice were somewhat surprising. GM-CSF mRNA was detectable in peritoneal cells but at a far lower level than in transgenic ␤c +/+ mice, in agreement with the bioassay results on peritoneal cell-conditioned media. Lung mRNA was possibly elevated compared with non-transgenic mice but the most surprising result was the very high level of GM-CSF mRNA in the eye of transgenic ␤c −/− mice, since this organ was histologically normal. This casts doubt on the original explanation for the high GM-CSF mRNA in transgenic eyes and suggests the occurrence of a selective tissue-directed expression of the transgene in this particular organ.
The data supported the conclusion that GM-CSF transgenic ␤c −/− peritoneal macrophages were not producing particularly high levels of GM-CSF, making the model an imperfect test for the action of an internally produced regulator on a responsive cell type. The other conclusion emerging was that overall transcription of GM-CSF in transgenic ␤c −/− mice was
Figure 1
The morphology of peritoneal cell populations from (A) a normal mouse, (B) a GM-CSF transgenic ␤c +/+ mouse, and (C) a GM-CSF transgenic ␤c −/− mouse. Note the normal pleiomorphic appearance of the macrophages and the presence of lymphocytes and mast cells in the population from the GM-CSF transgenic ␤c −/− mouse. much lower than in transgenic ␤c +/+ mice. This indicated that some other mechanism must be responsible for the fact that GM-CSF levels were five times higher in transgenic ␤c −/− than in transgenic ␤c +/+ mice, the most likely being a difference in GM-CSF clearance and/or excretion.
Clearance of plasma GM-CSF in ␤c −/− mice If, as is commonly held, receptor-mediated endocytosis is a major fate of circulating regulators, 1, [19] [20] [21] circulating levels of the regulator should be more sustained in animals lacking high-affinity receptors for the ligand. Previous studies using
Figure 2
The morphology of the eye from (A) a normal mouse, (B) a GM-CSF transgenic ␤c +/+ mouse, and (C) a GM-CSF transgenic ␤c −/− mouse. Note the absence of macrophage infiltrate and no destruction of the retina or lens in the GM-CSF transgenic ␤c −/− mouse.
intravenously injected 125 I-labeled non-glycosylated GM-CSF failed to reveal a difference in the plasma half-life of the injected GM-CSF between ␤c −/− and ␤c +/+ mice. 11 However, when these experiments were repeated using bioassays to detect bioactive GM-CSF, the half-life of both nonglycosylated and glycosylated GM-CSF was significantly prolonged in non-transgenic ␤c −/− compared with ␤c +/+ mice ( Figure 5 ). This approach could not be used with the GM-CSF transgenic mice because of the high pre-existing levels of GM-CSF but the slower clearance noted in non-transgenic ␤c −/− mice could have contributed to the higher serum GM-CSF levels in the GM-CSF transgenic ␤c −/− mice than observed in other genotypes.
Figure 3
The morphology of the lung from (A) a normal mouse, (B) a non-transgenic ␤c −/− mouse, and (C) a GM-CSF transgenic ␤c −/− mouse. Note that the GM-CSF transgenic state did not alter the development of alveolar proteinosis or peribronchial lymphoid aggregates.
Urine clearance of GM-CSF When GM-CSF was injected intravenously into nontransgenic ␤c −/− mice, the amount of GM-CSF appearing in the urine in the following 5 h was consistently higher than observed using ␤c +/+ mice (Table 5 ). This suggested that GM-CSF receptors on kidney cells might be responsible for removing transfiltered GM-CSF from the urine, either for subsequent degradation or return to the plasma. To determine whether this removal system could be overloaded, the experiments were repeated using five times the amount of injected GM-CSF. However, as shown in Table 5 , this resulted in only a two-to four-fold rise in urine GM-CSF and no change in the difference observed between ␤c −/− and ␤c +/+ mice. It should be noted from Table 5 that although GM-CSF was undoubtedly cleared in the urine, the amount cleared was only a minute fraction (at most, 0.13%) of the amount of GM-CSF injected and could not have contributed significantly to the observed fall in plasma GM-CSF levels in ␤c −/− mice during this period.
In line with the deduction that the kidney has functionally active GM-CSF receptors, autoradiographs of kidneys 4 h after the injection of 125 I-labeled GM-CSF indicated selective labeling of proximal tubule cells (Figure 6 ) but no labeling of glomerular cells or distal tubule cells. This pattern is distinct from that observed previously with IL-3 15 and G-CSF. However the implications of this labeling are obscure because parallel studies using ␤c −/− mice observed selective tubular location of labeling of similar intensity after the injection of 125 I-GM-CSF ( Figure 6 ). In both cases, the GM-CSF used was non-glycosylated, eliminating the operation of some carbohydrate-clearing cellular receptor mechanism.
Discussion
The present experiments were undertaken in part as a critical test of current dogma on the respective roles played by the glycoprotein regulators and their membrane receptors in initiating cellular responses. 1 It is believed at present that regulators serve only to cross-link membrane receptor chains and allow their subsequent functional activation to initiate signaling. At no stage is the regulator itself held to interact with signaling molecules. Furthermore, the low-affinity regulator-␣ receptor chain complexes are not only transient but do not lead to activation or internalization. 22 While these views are supported by a large body of experimental evidence, they do not address one situation of known importance in leukemogenesis -the autocrine production of a growth factor within a cell responsive to that growth factor. [2] [3] [4] In this situation, the assumption is made that the growth factor remains cell-associated and complexes with receptors to initiate conventional signaling responses. The acutal situation is somewhat obscure because, when antibodies to the growth factor are added to the medium, these do not necessarily block the subsequent autonomous proliferation in vitro of some autocrine growth factor-producing cells. 23 Given that growth factors have a highly specific configuration, are of a size approximating receptors and that regulators and receptor chains enter the cells in equal numbers, it seems slightly improbable that the growth factor has no role whatsoever other than to serve as a cross-linker of receptor chains, particularly if, in autocrine situations, the growth factor is already intracellularly located.
The model used involved the generation of mice with overexpression of the transgenic GM-CSF in cells usually able to exhibit changes induced by the GM-CSF but now only expressing low-affinity receptor ␣-chains and no ␤ chains that are needed to complete the high-affinity receptor complex to initiate cellular signaling. Any cellular changes noted would then indicate either an action of low-affinity GM-CSF-␣-chain receptor complexes or a direct intracellular action of GM-CSF itself. Essentially all information on GM-CSF receptors has been derived from studies on hematopoietic cells and, in principle, novel specific GM-CSF receptors could exist on other cell types and allow responsiveness of these tissues in ␤c −/− mice. However, the cDNA encoding the ␣-GM-CSF receptor was originally cloned from a placental cDNA library 24 and could possibly have come from a non-hematopoietic cell.
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Figure 4
Levels of tissue GM-CSF mRNA detected by RT-PCR in organs from a GM-CSF transgenic ␤c +/+, a GM-CSF transgenic ␤c −/− and a normal mouse. Note the increased levels of GM-CSF mRNA in the GM-CSF transgenic ␤c +/+ mouse and the lesser elevations in the GM-CSF transgenic ␤c −/− mouse with the notable exception of the eye.
Figure 5
The slower fall in serum levels of GM-CSF detected by bioassays in ␤c −/− compared with ␤c +/+ mice following the intravenous injection of glycosylated GM-CSF (upper panel) or non-glycosylated GM-CSF (lower panel). Data from three mice per timepoint, showing mean values ± standard deviations. Previous studies on the hematopoietic cells of ␤c −/− mice indicated that these cells are incapable of proliferative or survival responses to GM-CSF. 11 The mice develop a characteristic lung disease, alveolar proteinosis, whose basis is ascribable at least in part to failure of function of ␤c −/− alveolar macrophages. 11, 16, 17 The model used did achieve a mouse with spectacularly elevated serum GM-CSF levels although it did not achieve a peritoneal macrophage population producing particularly high levels of GM-CSF. Because these cells were the major population for testing the actions of GM-CSF in the absence of high-affinity receptors, the test system fell short of being an optimal one that could unequivocally eliminate the possibility of non-receptor-mediated actions. The failure of these ␤c −/− macrophages to produce high levels of GM-CSF strongly sug-gests that, in the usual GM-CSF transgenic mouse, an autocatalytic element is operating in which macrophages produce GM-CSF or IL-1 that, in turn, stimulates the producing cells to enlarge and become functionally activated to produce yet more GM-CSF.
The major pathological consequences of the GM-CSF transgenic state are destruction of tissues of the eye and accumulation of massive numbers of macrophages in the peritoneal and pleural cavities, associated with changes in the nuclear morphology of these macrophages, cytoplasmic enlargement and basophilia and a tendency with time to form multinucleated macrophages by cell fusion.
8, 9 Associated changes in peritoneal populations are a consistent rise in eosinophil numbers, a depletion of mast cells and a variable rise in neutrophils in the peritoneal cavity. More variable are the development of inflammatory macrophage-containing nodules in the peritoneal and pleural cavity, in skeletal muscle and bladder and a generalized wasting disease with hind limb weakness or paralysis. 9, 10 Although the transgenic ␤c −/− mice did not achieve optimal levels of autocrine GM-CSF production by macrophages, the mice unequivocally demonstrated none of this multiplicity of tissue changes. Eye structure was normal, peritoneal populations were normal in total numbers, and the more subtle parameters of cellular composition and morphology and no tissue lesions were observed in any organ. The complete absence of any tissue changes is proof that the various lesions of GM-CSF transgenic mice are indeed initiated by GM-CSF and not due to some insertional artifact dependent on the inserted transgene accidentally disrupting the function of adjacent genes. 10 The data also indicate that ␣-chain binding of GM-CSF is without observable impact on subtle parameters not previously considered such as nuclear morphology, cell fusion, cytoplasmic basophilia or size.
It has been proposed that the tissue lesions in GM-CSF transgenic mice are macrophage-mediated with the ultimate death of the mice from wasting disease and paralysis, the consequence of macrophage production of agents such as TNF␣, IL-1 and ␥-interferon. 9, 18, 25 The failure of ␤c −/− mice to develop activated macrophage populations and to develop tissue lesions supports this general hypothesis but also eliminates a less likely possibility that other types of GM-CSF receptor might be present in these tissues and be able to mediate direct toxic effects of GM-CSF on these tissues.
The lung disease of ␤c −/− (or GM-CSF −/−) mice is an opposite situation where the disease state has been ascribed to macrophage hypofunction rather than hyperfunction. 11, 16, 17 The lesions in GM-CSF −/− mice can in fact be corrected by local lung epithelial expression of transgenic GM-CSF. 26 The presence of excess levels of GM-CSF in GM-CSF transgenic ␤c −/− mice had no impact on the occurrence or severity of the lung pathology.
An intriguing aspect of the present transgenic ␤c −/− mice was the extremely high serum and urine levels of GM-CSF achieved in the absence of any comparable elevation of GM-CSF production. This argues strongly that the production rates of GM-CSF are not the dominant parameter in determining circulating levels and that utilization or clearance can be factors of equal or greater importance. What remains unclear is the nature of these utilization/clearance systems. The half-life of plasma GM-CSF was clearly extended in ␤c −/− mice, documenting the role of receptor-mediated degradation. However GM-CSF levels did fall in ␤c −/− mice, indicating the extence of other types of clearance mechanisms. Because the same was true when non-glycosylated GM-CSF was used, carbohydrate clearance systems cannot provide a complete explanation.
Urine clearance of GM-CSF was documented, as was a role for GM-CSF receptors in decreasing this process, but again uncertainty exists because ␤c −/− tubule cells bound 125 Ilabeled GM-CSF in a similar manner to ␤c +/+ cells, suggesting the existence again of some alternative membrane recognition system for removing GM-CSF. Although urine GM-CSF levels were consistently elevated in GM-CSF transgenic ␤c −/− mice, the data on clearance of injected GM-CSF indicated that elimination of GM-CSF in the urine is only a minor fate of circulating GM-CSF and can therefore only be a minor factor in determining the fall with time in plasma GM-CSF levels.
The analysis of the GM-CSF transgenic ␤c −/− mice has provided no evidence to contest the current view that the action of GM-CSF or comparable glycoprotein regulators, is entirely dependent on activation of specific high-affinity membrane receptors. Interaction with specific low-affinity receptors appeared to be unable to induce or correct any hematopoietic or tissue changes. The failure to achieve peritoneal macrophages in these mice that produced very high levels of GM-CSF does leave the question of the consequences of autocrine production less satisfactorily resolved, although the levels of production achieved were comparable with those often seen in autocrine myeloid leukemic cells. 
